domvanalimab + zimberelimab + docetaxel

This drug is a **combination therapy** consisting of domvanalimab (an Fc-silent monoclonal antibody targeting TIGIT), zimberelimab (an anti-PD-1 monoclonal antibody), and docetaxel (a cytotoxic chemotherapy agent). - **Domvanalimab** is designed to block and bind TIGIT, a checkpoint protein that suppresses immune activation in the tumor microenvironment. Its action is intended to enhance T cell and natural killer cell responses against cancer cells by lifting the immune suppression mediated via TIGIT. - **Zimberelimab** targets programmed death-1 (PD-1), an inhibitory receptor on T cells, thereby promoting T cell activity by blocking PD-1/PD-L1 immune checkpoint interaction, which tumors exploit for immune evasion. - **Docetaxel** is a taxane-class chemotherapy agent that inhibits microtubule depolymerization, arresting cell division and inducing cell death. This combination is under investigation for the treatment of various advanced solid tumors, including metastatic or unresectable **non-small cell lung cancer (NSCLC)** and upper gastrointestinal cancers. The rationale is that dual immune checkpoint inhibition (TIGIT + PD-1) with chemotherapy may provide enhanced and synergistic anti-tumor effects over standard regimens[1][2][3][4]. - Developed collaboratively by Arcus Biosciences and Gilead Sciences.